- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
CDSCO Panel Clears PURE & CURE's Sickle Cell Trial With Conditions On Sample Size, Sites

New Delhi: PURE & CURE Healthcare Pvt. Ltd. has received a recommendation from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) to conduct a Phase IV clinical trial of Hydroxyurea Oral Suspension 100 mg/mL in patients over 2 years of age suffering from Sickle Cell Disease. However, the approval comes with two key conditions: the sample size must be increased to 200 patients, and the trial sites must be selected from Chhattisgarh and Nagpur, regions with a high prevalence of the disease.
The recommendation came during the 08th meeting of the SEC (Haematology) held on 15th July 2025 at CDSCO headquarters, New Delhi.
The firm had presented its proposal seeking permission to conduct a Phase IV study titled: “A Phase IV Clinical Trial of Hydroxyurea Oral Suspension 100 mg/mL for the Prevention of Vaso-Occlusive Complications of Sickle Cell Disease in Patients Over 2 Years of Age.” The proposed trial will be conducted in accordance with Protocol No. SB-ICMR-CT-001, Version 1.0, dated 22 January 2024.
Hydroxyurea is a widely used therapy in sickle cell disease and works by increasing fetal hemoglobin levels, thereby reducing the frequency of vaso-occlusive crises, which are painful episodes caused by blockage of blood vessels due to sickled red blood cells.
Following a detailed review, the SEC recommended permission to proceed with the trial but asked the firm to incorporate two important changes to the study design. First, the sample size must be increased to 200 patients to enhance the statistical robustness of the findings. Second, the clinical trial sites should be selected from Chhattisgarh and Nagpur, regions with a high prevalence of sickle cell disease, ensuring relevant population representation.
“After detail deliberation, the Committee recommended to grant the permission to conduct clinical trial as per protocol presented with following changes: 1. The sample size should be increased to 200 patients 2. Recruit clinical trial sites from the Chhattisgarh and Nagpur areas where the disease is prevalent,” the SEC noted in its recommendation.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751